Table 3.
Subgroup Analysis According to Study Participants’ Obesity Status
| Number | Repeat PCI | Duration | IR, /1,000 PY | Model 1 | P for interaction | Model 2 | P for interaction | |
|---|---|---|---|---|---|---|---|---|
| BMI <25 kg/m2 | ||||||||
| Insulin | ||||||||
| No | 10,603 | 1,240 | 45,748.36 | 27.1 | 1 (reference) | 0.1571 | 1 (reference) | 0.1710 |
| Yes | 8,096 | 1,084 | 33,123.32 | 32.7 | 1.19 (1.10–1.29) | 1.09 (1.00–1.19) | ||
| Sulfonylurea | ||||||||
| No | 7,401 | 847 | 30,927.41 | 27.4 | 1 (reference) | 0.2569 | 1 (reference) | 0.2875 |
| Yes | 11,298 | 1,477 | 47,944.27 | 30.8 | 1.14 (1.05–1.24) | 1.03 (0.92–1.16) | ||
| Metformin | ||||||||
| No | 4,397 | 568 | 18,102.88 | 31.4 | 1 (reference) | 0.4407 | 1 (reference) | 0.4181 |
| Yes | 14,302 | 1,756 | 60,768.8 | 28.9 | 0.93 (0.84–1.02) | 0.75 (0.66–0.86) | ||
| Meglitinides | ||||||||
| No | 17,725 | 2,164 | 74,917.41 | 28.9 | 1 (reference) | 0.8760 | 1 (reference) | 0.8469 |
| Yes | 974 | 160 | 3,954.27 | 40.5 | 1.41 (1.20–1.65) | 1.28 (1.09–1.51) | ||
| TZD | ||||||||
| No | 17,822 | 2,206 | 75,248.53 | 29.3 | 1 (reference) | 0.0216 | 1 (reference) | 0.0139 |
| Yes | 877 | 118 | 3,623.15 | 32.6 | 1.11 (0.92–1.33) | 1.05 (0.87–1.26) | ||
| DPP4i | ||||||||
| No | 11,945 | 1,500 | 51,987.36 | 28.9 | 1 (reference) | 0.4574 | 1 (reference) | 0.5158 |
| Yes | 6,754 | 824 | 26,884.32 | 30.6 | 1.01 (0.93–1.10) | 0.92 (0.83–1.02) | ||
| AGI | ||||||||
| No | 15,409 | 1,818 | 64,369.28 | 28.2 | 1 (reference) | 0.7990 | 1 (reference) | 0.7794 |
| Yes | 3,290 | 506 | 14,502.40 | 34.9 | 1.29 (1.17–1.42) | 1.23 (1.10–1.37) | ||
|
| ||||||||
| BMI ≥25 kg/m2 | ||||||||
| Insulin | ||||||||
| No | 10,301 | 1,200 | 45,639.27 | 26.3 | 1 (reference) | 0.1571 | 1 (reference) | 0.1710 |
| Yes | 6,348 | 921 | 26,619.82 | 34.6 | 1.30 (1.19–1.41) | 1.21 (1.11–1.33) | ||
| Sulfonylurea | ||||||||
| No | 6,941 | 853 | 29,907.94 | 28.5 | 1 (reference) | 0.2569 | 1 (reference) | 0.2875 |
| Yes | 9,708 | 1,268 | 42,351.14 | 29.9 | 1.06 (0.97–1.16) | 1.04 (0.93–1.18) | ||
| Metformin | ||||||||
| No | 4,060 | 563 | 17,432.53 | 32.3 | 1 (reference) | 0.4407 | 1 (reference) | 0.4181 |
| Yes | 12,589 | 1,558 | 54,826.55 | 28.4 | 0.88 (0.80–0.97) | 0.79 (0.69–0.91) | ||
| Meglitinides | ||||||||
| No | 15,997 | 2,011 | 69,482.59 | 28.9 | 1 (reference) | 0.8760 | 1 (reference) | 0.8469 |
| Yes | 652 | 110 | 2,776.49 | 39.6 | 1.38 (1.14–1.67) | 1.24 (1.02–1.51) | ||
| TZD | ||||||||
| No | 15,730 | 2,026 | 68,246.6 | 29.7 | 1 (reference) | 0.0216 | 1 (reference) | 0.0139 |
| Yes | 919 | 95 | 4,012.49 | 23.7 | 0.80 (0.65–0.98) | 0.77 (0.63–0.95) | ||
| DPP4i | ||||||||
| No | 10,904 | 1,424 | 48,687.84 | 29.2 | 1 (reference) | 0.4574 | 1 (reference) | 0.5158 |
| Yes | 5,745 | 697 | 23,571.24 | 29.6 | 0.96 (0.88–1.06) | 0.95 (0.85–1.07) | ||
| AGI | ||||||||
| No | 14,442 | 1,772 | 62,091.90 | 28.5 | 1 (reference) | 0.7990 | 1 (reference) | 0.7794 |
| Yes | 2,207 | 349 | 10,167.19 | 34.3 | 1.26 (1.12–1.41) | 1.25 (1.10–1.41) | ||
The incidence rate is presented per 1,000 person-years (PY).
Values are expressed as hazard ratio (95% confidence interval). Model 1: Unadjusted; Model 2: Adjusted for household income, hypertension, dyslipidemia, current smoking, alcohol, regular exercise, BMI, use of insulin, number of oral antidiabetic drugs, fasting blood glucose, and duration of diabetes.
PCI, percutaneous coronary intervention; IR, incidence rate; BMI, body mass index; TZD, thiazolidinedione; DPP4i, dipeptidyl peptidase-4 inhibitor; AGI, alpha-glucosidase inhibitor.